Novo Nordisk (NVO) Signed a MOU With Fangzhou Inc to Focus on Chronic Diseases

Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right NowOn July 18, Novo Nordisk A/S (NYSE:NVO) announced signing a Memorandum of Understanding with Fangzhou Inc., which is a leading internet healthcare solution provider.

The collaboration focuses on managing serious chronic diseases like diabetes and obesity through AI and innovative healthcare technologies. Fangzhou will use its AI applications and smart healthcare ecosystem alongside Novo Nordisk A/S (NYSE:NVO)’s expertise in diabetes and obesity treatment. Both companies aim to develop health management services that include guidance, reminders, treatment monitoring, and health education.

Novo Nordisk (NVO) Signed a MOU With Fangzhou Inc to Focus on Chronic Diseases

An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.

Novo Nordisk A/S (NYSE:NVO) is an international pharmaceutical company specializing primarily in diabetes care and obesity disorders.

While we acknowledge the potential of NVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.